Cover Image
市場調查報告書

色素沉着絨毛結節性滑膜炎:開發中產品分析

Pigmented Villonodular Synovitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360914
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
色素沉着絨毛結節性滑膜炎:開發中產品分析 Pigmented Villonodular Synovitis - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 46 Pages
簡介

本報告提供色素沉着絨毛結節性滑膜炎治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

色素沉着絨毛結節性滑膜炎概要

治療藥的開發

  • 開發中產品的概要

色素沉着絨毛結節性滑膜炎:企業開發中的治療藥

色素沉着絨毛結節性滑膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

色素沉着絨毛結節性滑膜炎:企業開發中的產品

色素沉着絨毛結節性滑膜炎治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Novartis AG
  • Plexxikon Inc.

色素沉着絨毛結節性滑膜炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

色素沉着絨毛結節性滑膜炎:最近的開發平台趨勢

色素沉着絨毛結節性滑膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9371IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H1 2017, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape.

Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 3 and 2 respectively.

Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pigmented Villonodular Synovitis - Overview
    • Pigmented Villonodular Synovitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Pigmented Villonodular Synovitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd
    • Five Prime Therapeutics Inc
    • Novartis AG
    • Plexxikon Inc
  • Pigmented Villonodular Synovitis - Drug Profiles
    • cabiralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-73086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pigmented Villonodular Synovitis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting
      • Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis
      • Jan 24, 2017: European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis
      • May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis
      • Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis
      • Jul 13, 2015: Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis
      • Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis
      • May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting
      • May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pigmented Villonodular Synovitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pigmented Villonodular Synovitis - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H1 2017
  • Pigmented Villonodular Synovitis - Pipeline by Plexxikon Inc, H1 2017

List of Figures

  • Number of Products under Development for Pigmented Villonodular Synovitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top